Telix Pharmaceuticals (NASDAQ:TLX) Hits New 52-Week Low - Time to Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares reached a new 52-week low during trading on Wednesday . The company traded as low as $7.29 and last traded at $7.26, with a volume of 11340 shares trading hands. The stock had previously closed at $7.73.Get Telix Pharmaceuticals alerts:Wall Street Analyst Weigh InA number of equities research analysts have recently commented on TLX shares. Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday. Wall Street Zen cut shares of Telix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, December 20th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a "strong-buy" rating in a research report on Monday, October 6th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $21.00.Get Our Latest Research Report on TLXTelix Pharmaceuticals Price PerformanceThe business's 50-day moving average price is $8.56 and its 200 day moving average price is $10.46. Institutional Trading of Telix PharmaceuticalsInstitutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the third quarter valued at approximately $1,883,000. Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at $1,225,000. Lazard Asset Management LLC bought a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth about $975,000. Telix Pharmaceuticals Company Profile (Get Free Report)Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides. The company’s pipeline spans both imaging and therapeutic candidates.See AlsoFive stocks we like better than Telix PharmaceuticalsElon Taking SpaceX Public! $100 Pre-IPO Opportunity!How a Family Trust May Be Able To Help Preserve Your WealthDo not delete, read immediatelyA U.S. “birthright” claim worth trillions - activated quietlyExecutive Order 14330: Trump’s Biggest YetThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Telix Pharmaceuticals Right Now?Before you consider Telix Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here